Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Mirikizumab-mrkz, an interleukin-23 antagonist, was recently approved for the treatment of moderately to severely active CD in adults under the brand name Omvoh TM. The product is also indicated ...

These growth stocks come from two very different industries. Eli Lilly is riding the GLP-1 drug wave, but there is much more to this business for investors to like. Chewy is advancing its e-commerce ...

We received approval for a new indication of Zepbound and Omvoh. We submitted imlunestrant ... consumers and raising awareness for that brand. Zepbound have full PBM coverage already.